Abstract B32: The impact of PET-CT on staging, management, and prognostication of small cell lung cancer.

2014 ◽  
Vol 20 (2 Supplement) ◽  
pp. B32-B32
Author(s):  
Alona Zer ◽  
Yael Rapson ◽  
Meital Nadam ◽  
Dov Flex ◽  
Aaron M. Allen ◽  
...  
2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 6611-6611
Author(s):  
Alona Zer ◽  
Yael Rapson ◽  
Meital Nadam ◽  
Dov Flex ◽  
Aaron Allen ◽  
...  

2013 ◽  
Vol 106 (3) ◽  
pp. 288-291 ◽  
Author(s):  
Sarah Everitt ◽  
Nikki Plumridge ◽  
Alan Herschtal ◽  
Mathias Bressel ◽  
David Ball ◽  
...  

Author(s):  
Seyyed Ali Hosseini ◽  
Isaac Shiri ◽  
Ghasem Hajianfar ◽  
Pardis Ghafarian ◽  
Mehrdad Bakhshayesh Karam ◽  
...  

Purpose: This study aimed to investigate the impact of image preprocessing steps, including Gray Level Discretization (GLD) and different Interpolation Algorithms (IA) on 18F-Fluorodeoxyglucose (18F-FDG) radiomics features in Non-Small Cell Lung Cancer (NSCLC). Materials and Methods: One hundred and seventy-two radiomics features from the first-, second-, and higher-order statistic features were calculated from a set of Positron Emission Tomography/Computed Tomography (PET/CT) images of 20 non-small cell lung cancer delineated tumors with volumes ranging from 10 to 418 cm3 regarding five intensity discretization schemes with the number of gray levels of 16, 32, 64, 128, and 256, and four Interpolation algorithms, including nearest neighbor, tricubic convolution and tricubic spline interpolation, and trilinear were used. Segmentation was based on 3D region growing-based. The Intraclass Correlation Coefficient (ICC), Overall Concordance Correlation Coefficient (OCCC), and Coefficient Of Variations (COV) were calculated to demonstrate the features' variability and select robust features. ICC and OCCC < 0.5 presented weak reliability, ICC and OCCC between 0.5 and 0.75 illustrated appropriate reliability, values within 0.75 and 0.9 showed satisfying reliability, and values higher than 0.90 indicate exceptional reliability. Besides, features with less than 10% COV have been selected as robust features. Results: All morphology family (except four features), statistic, and Intensity volume histogram families were not affected by GLD and IA. And the rest of them, 10 and 61 features showed COV ≤ 5% against GLD and IA, respectively. Ten and 80 features showed excellent reliability (ICC values greater than 0.90) against GLD and IA. Eight and 60 features showed OCCC≥0.90 against GLD and IA, respectively. Based on our results Inverse difference normalized and Inverse difference moment normalized from Grey Level Co-occurrence Matrix (GLCM) were the most robust features against GLD and Skewness from intensity histogram family and Inverse difference normalized and Inverse difference moment normalized from GLCM were the most robust features against IA. Conclusion: Preprocessing can substantially impact the 18F-FDG PET image radiomic features in NSCLC. The impact of gray level discretization on radiomics features is significant and more than Interpolation algorithms.


2018 ◽  
Vol 13 (10) ◽  
pp. S351 ◽  
Author(s):  
P. Manorharan ◽  
A. Salem ◽  
H. Mistry ◽  
M. Gornall ◽  
S. Harden ◽  
...  

2019 ◽  
Vol 15 (1) ◽  
pp. 50-55
Author(s):  
Ahmed Nagy ◽  
Omar Abdel Rahman ◽  
Heba Abdullah ◽  
Ahmed Negida

Background: Although well established for the effective management of hematologic cancers, maintenance chemotherapy has only been recently incorportated as a treatment paradigm for advanced non–small-cell lung cancer. Maintenance chemotherapy aims to prolong a clinically favorable response state achieved after finishing induction therapy which is usually predefined in number before startng treatment. There are 2 modalities for maintenance therapy; continuation maintenance (involving a non-platinum component which was a part of the induction protocol or a targeted agent) and switch maintenance therapy (utilizing a new agent which was not a part of the induction regimen). Methods: The purpose of this article is to review the role of maintenance therapy in the treatment of advanced Non-Small Cell Lung Cancer (NSCLC) and provide a brief overview about induction chemotherapy in NSCLC to address the basis of maintenance therapy as a treatment option. We will also compare the impact of maintenance chemotherapy with the now evolving role of immunotherapy in NSCLC. Results: There have been 4 maintenance studies to date showing prolonged PFS and OS with statistical significance. However, Three out of the four studies (ECOG4599, JMEN, and PARAMOUNT) did not report tumor molecular analysis. As regard Immunotherapy, current data is in favour of strongly an increasing role for immunotherapy in NSCLC. Conclusion: Maintenance therapy in NSCLC continues to be an important therapeutic line to improve outcome in patients with metastatic and recurrent disease.


2016 ◽  
Vol 27 ◽  
pp. ix153-ix154
Author(s):  
T. Miyawaki ◽  
S. Yagishita ◽  
R. Ko ◽  
Y. Suzuki ◽  
N. Matsumoto ◽  
...  

2021 ◽  
Vol 9 (4) ◽  
pp. e002421
Author(s):  
Alessio Cortellini ◽  
Massimo Di Maio ◽  
Olga Nigro ◽  
Alessandro Leonetti ◽  
Diego L Cortinovis ◽  
...  

BackgroundSome concomitant medications including antibiotics (ATB) have been reproducibly associated with worse survival following immune checkpoint inhibitors (ICIs) in unselected patients with non-small cell lung cancer (NSCLC) (according to programmed death-ligand 1 (PD-L1) expression and treatment line). Whether such relationship is causative or associative is matter of debate.MethodsWe present the outcomes analysis according to concomitant baseline medications (prior to ICI initiation) with putative immune-modulatory effects in a large cohort of patients with metastatic NSCLC with a PD-L1 expression ≥50%, receiving first-line pembrolizumab monotherapy. We also evaluated a control cohort of patients with metastatic NSCLC treated with first-line chemotherapy. The interaction between key medications and therapeutic modality (pembrolizumab vs chemotherapy) was validated in pooled multivariable analyses.Results950 and 595 patients were included in the pembrolizumab and chemotherapy cohorts, respectively. Corticosteroid and proton pump inhibitor (PPI) therapy but not ATB therapy was associated with poorer performance status at baseline in both the cohorts. No association with clinical outcomes was found according to baseline statin, aspirin, β-blocker and metformin within the pembrolizumab cohort. On the multivariable analysis, ATB emerged as a strong predictor of worse overall survival (OS) (HR=1.42 (95% CI 1.13 to 1.79); p=0.0024), and progression free survival (PFS) (HR=1.29 (95% CI 1.04 to 1.59); p=0.0192) in the pembrolizumab but not in the chemotherapy cohort. Corticosteroids were associated with shorter PFS (HR=1.69 (95% CI 1.42 to 2.03); p<0.0001), and OS (HR=1.93 (95% CI 1.59 to 2.35); p<0.0001) following pembrolizumab, and shorter PFS (HR=1.30 (95% CI 1.08 to 1.56), p=0.0046) and OS (HR=1.58 (95% CI 1.29 to 1.94), p<0.0001), following chemotherapy. PPIs were associated with worse OS (HR=1.49 (95% CI 1.26 to 1.77); p<0.0001) with pembrolizumab and shorter OS (HR=1.12 (95% CI 1.02 to 1.24), p=0.0139), with chemotherapy. At the pooled analysis, there was a statistically significant interaction with treatment (pembrolizumab vs chemotherapy) for corticosteroids (p=0.0020) and PPIs (p=0.0460) with respect to OS, for corticosteroids (p<0.0001), ATB (p=0.0290), and PPIs (p=0.0487) with respect to PFS, and only corticosteroids (p=0.0033) with respect to objective response rate.ConclusionIn this study, we validate the significant negative impact of ATB on pembrolizumab monotherapy but not chemotherapy outcomes in NSCLC, producing further evidence about their underlying immune-modulatory effect. Even though the magnitude of the impact of corticosteroids and PPIs is significantly different across the cohorts, their effects might be driven by adverse disease features.


Sign in / Sign up

Export Citation Format

Share Document